Nanobiotix (NBTX) said Monday its JNJ-1900 drug candidate showed a median overall survival of 23 months for certain patients with pancreatic cancer in a phase 1 study.
A historical review of 144 patients with locally advanced pancreatic cancer treated at the same center showed a median overall survival of 19.2 months, the company said.
The drug, jointly developed with Johnson & Johnson (JNJ) subsidiary Janssen Pharmaceutica, also showed a favorable safety profile, Nanobiotix said.
The company added that the results prompted investigators to recommend further evaluation in a randomized study. The US Food and Drug Administration has also cleared researchers to expand the study to include a new cohort that has already recruited and dosed its first patient, the company said.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。